Critical Metals Corp. (CRML) entered into a securities purchase agreement with institutional investors to sell 5,999,998 ordinary shares in a private placement priced at $10.00 per share, generating gross proceeds of approximately $60 million. The transaction is expected to close on or about April 22, 2026 and is being facilitated by Clear Street LLC as placement agent.
The company will use the net proceeds to fund working capital needs and to accelerate development of its Tanbreez rare‑earth project in southern Greenland. Tanbreez, which the company now controls 92.5% of, is a world‑class heavy rare‑earth asset that is strategically important for Western supply chains seeking to reduce dependence on China.
"Today marks a pivotal milestone for CRML with the successful pricing of a $60 million common equity financing, underscoring the confidence our partners and investors have in our vision, team and long‑term potential," said CEO and Chairman Tony Sage. "This capital accelerates our expansion and positions CRML to emerge as a global leader in Critical Metals, while strengthening our foundation to create significant value for shareholders and the broader industry."
The announcement was met with concerns about dilution, leading to a muted market response. Investors focused on the immediate impact of issuing new shares, while also recognizing the strategic importance of the financing for advancing the Tanbreez project.
The Tanbreez project is a key driver of the company’s future growth. Its development supports Western efforts to secure critical rare‑earth supplies for clean‑energy, defense, and advanced technology applications. The financing strengthens CRML’s ability to move the project closer to production, reinforcing its position as a leading critical‑minerals developer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.